Heparan sulfate proteoglycans as targets for cancer therapy: a review

Reference

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clini. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–74. doi:10.1016/j.cell.2011.02.013. PMID: 21376230
   Google Scholar
• Blackhall FH, Merry CL, Davies E, Jayson GC. Heparan sulfate proteoglycans and cancer. Br J Cancer. 2001;85(8):1094. doi:10.1054/bjoc.2001.2054.
   PubMed Web of Science ®Google Scholar
• Brunetti J, Depau L, Falciani C, Gentile M, Mandarini E, Riolo G, Lupetti P, Pini A, Bracci L. Insights into the role of sulfated glycans in cancer cell adhesion and migration through use of branched peptide probe. Scientific reports 2016; 6:27174
   Google Scholar
• Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011;3(7):a004952. doi:10.1101/cshperspect.a004952.
   PubMed Web of Science ®Google Scholar
• Lopes CC, Dietrich CP, Nader HB. Specific structural features of syndecans and heparan sulfate chains are needed for cell signaling. Braz J Med Biol Res. 2006;39(2):157–167. doi:10.1590/S0100-879X2006000200001.
   PubMed Web of Science ®Google Scholar
• Noonan DM, Hassell JR. Perlecan, the large low-density proteoglycan of basement membranes: structure and variant forms. Kidney Int. 1993;43(1):53–60. doi:10.1038/ki.1993.10.
   PubMed Web of Science ®Google Scholar
• Jiang X, Couchman JR. Perlecan and tumor angiogenesis. J Histochemistry & Cytochemistry. 2003;51(11):1393–1410. doi:10.1177/002215540305101101.
   PubMed Web of Science ®Google Scholar
• Kaur SP, Cummings BS. Role of glypicans in regulation of the tumor microenvironment and cancer progression. Biochem Pharmacol. 2019;168:108–118. doi:10.1016/j.bcp.2019.06.020.
   PubMed Web of Science ®Google Scholar
• Filmus J, Capurro M, Rast J. Glypicans. Genome Biol. 2008;9(5):224. doi:10.1186/gb-2008-9-5-224.
   PubMed Web of Science ®Google Scholar
• Morla S. Glycosaminoglycans and glycosaminoglycan mimetics in cancer and inflammation. Int J Mol Sci. 2019;20(8):1963. doi:10.3390/ijms20081963.
   Web of Science ®Google Scholar
• Ibrahim SA, Gadalla R, El-Ghonaimy EA, Samir O, Mohamed HT, Hassan H, Greve B, El-Shinawi M, Mohamed MM, Götte M. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Molecular cancer 2017; 16: 57
   Google Scholar
• Péterfia B, Füle T, Baghy K, Szabadkai K, Fullár A, Dobos K, Zong F, Dobra K, Hollósi P, Jeney A. Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2. PloS one 2012; 7:e39474
   PubMed Web of Science ®Google Scholar
• Lee J-H, Park H, Chung H, Choi S, Kim Y, Yoo H, Kim T-Y, Hann H-J, Seong I, Kim J. Syndecan-2 regulates the migratory potential of melanoma cells. J Biol Chem. 2009;284(40):27167–27175. doi:10.1074/jbc.M109.034678.
   PubMed Web of Science ®Google Scholar
• De Oliveira T, Abiatari I, Raulefs S, Sauliunaite D, Erkan M, Kong B, Friess H, Michalski CW, Kleeff J. Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype. Molecular cancer 2012; 11: 19
   Google Scholar
• Choi S, Choi Y, Jun E, Kim I-S, Kim S-E, Jung S-A, Oh E-S. Shed syndecan-2 enhances tumorigenic activities of colon cancer cells. Oncotarget 2015; 6: 3874
   Google Scholar
• Kim JH, Park SC. Syndecan-2 methylation as a new biomarker for early detection of colorectal neoplasm. Gut Liver. 2018;12(5):479. doi:10.5009/gnl18286.
   PubMed Web of Science ®Google Scholar
• Roskams T, De Vos R, David G, Van Damme B, Desmet V. Heparan sulphate proteoglycan expression in human primary liver tumours. The J Pathol: A J Pathol Soc G B Irel. 1998;185(3):290–297.
   Google Scholar
• Carneiro BR, Pernambuco Filho PC, Mesquita AP, da Silva DS, Pinhal MA, Nader HB, Lopes CC. Acquisition of anoikis resistance up-regulates syndecan-4 expression in endothelial cells. PloS one 2014; 9:e116001
   PubMed Web of Science ®Google Scholar
• Lendorf ME, Manon-Jensen T, Kronqvist P, Multhaupt HA, Couchman JR. Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J Histochemistry & Cytochemistry. 2011;59(6):615–629.
   PubMed Web of Science ®Google Scholar
• Harada E, Serada S, Fujimoto M, Takahashi Y, Takahashi T, Hara H, Nakatsuka R, Sugase T, Nishigaki T, Saito Y. Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma. Oncotarget. 2017;8(15):24741. doi:10.18632/oncotarget.15799.
   PubMedGoogle Scholar
• Shimizu Y, Suzuki T, Yoshikawa T, Tsuchiya N, Sawada Y, Endo I, Nakatsura T. Cancer immunotherapy‐targeted glypican‐3 or neoantigens. Cancer science 2018; 109:531–41
   Google Scholar
• Amankwah EK, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Aben KK, Anton‐Culver H, Antonenkova N, Bruinsma F. Epithelial‐mesenchymal transition (EMT) gene variants and epithelial ovarian cancer (EOC) risk. Genetic epidemiology 2015; 39:689–97
   Google Scholar
• Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immunity Archive 2012; 12:14
   PubMedGoogle Scholar
• Orecchia P, Conte R, Balza E, Petretto A, Mauri P, Mingari MC, Carnemolla B. A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma. European journal of cancer 2013; 49:2022–33
   Google Scholar
• Orecchia P, Conte R, Balza E, Pietra G, Mingari MC, Carnemolla B. 2015. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. Oncotarget. 6(35):37426–37442. doi:10.18632/oncotarget.605510.18632/oncotarget.6055.
   PubMedGoogle Scholar
• Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, Laurent P, Sun R-X, Klein B, Dore J-M. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996;94(2):318–323. doi:10.1046/j.1365-2141.1996.d01-1811.x.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research 2009; 15:4028–37
   PubMed Web of Science ®Google Scholar
• Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett. 2014;588(2):377–382. doi:10.1016/j.febslet.2013.10.002.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Gold PJ, El-khoueiry A, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clinical Cancer Research 2013:clincanres. 2616.012
   Google Scholar
• Matsuzaki S, Serada S, Hiramatsu K, Nojima S, Matsuzaki S, Ueda Y, Ohkawara T, Mabuchi S, Fujimoto M, Morii E. Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer. International journal of cancer 2018; 142:1056–66
   PubMed Web of Science ®Google Scholar
• Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clinical Cancer Research. 2009;15(24):7479–7491. doi:10.1158/1078-0432.CCR-09-0636.
   PubMed Web of Science ®Google Scholar
• Suarez ER, Paredes-Gamero EJ, Del Giglio A, Dos Santos Tersariol IL, Nader HB, Pinhal MAS. Heparan sulfate mediates trastuzumab effect in breast cancer cells. BMC Cancer. 2013;13(1):444. doi:10.1186/1471-2407-13-444.
   PubMedGoogle Scholar
• Onyeisi JOS, Castanho de Almeida Pernambuco Filho P, de Araujo Lopes S, Nader HB, Lopes CC. Heparan sulfate proteoglycans as trastuzumab targets in anoikis-resistant endothelial cells. J Cell Biochem 2019; 120:13826–40
   Google Scholar
• Gialeli C, Theocharis A, Kletsas D, Tzanakakis G, Karamanos N. Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab. Invest New Drugs. 2013;31(3):516–524. doi:10.1007/s10637-012-9875-x.
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79(3):629–661. doi:10.1021/acs.jnatprod.5b01055.
   PubMed Web of Science ®Google Scholar
• Guimarães FS, Andrade LF, Martins ST, Abud AP, Sene RV, Wanderer C, Tiscornia I, Bollati-Fogolín M, Buchi DF, Trindade ES. In vitro and in vivo anticancer properties of a Calcarea carbonica derivative complex (M8) treatment in a murine melanoma model. BMC cancer 2010; 10: 113
   Google Scholar
• Das D, Das I, Das J, Koyal SK, Khuda-Bukhsh AR. Efficacy of two commonly used potentized homeopathic drugs, Calcarea carbonica and Lycopodium clavatum, used for treating polycystic ovarian syndrome (PCOS) patients: II Modulating effects on certain associated hormonal levels. TANG. 2016;6(1):41–47.
   Google Scholar
• Lan Y, Li X, Liu X, Hao C, Song N, Ren S, Wang W, Feng N, Zhang L. Genistein Enhances or Reduces Glycosaminoglycan Quantity in a Cell Type-Specific Manner. Cellular Physiology and Biochemistry 2018; 47:1667–81
   Google Scholar
• Chatzinikolaou G, Nikitovic D, Stathopoulos E, Velegrakis G, Karamanos N, Tzanakakis G. Protein tyrosine kinase and estrogen receptor-dependent pathways regulate the synthesis and distribution of glycosaminoglycans/proteoglycans produced by two human colon cancer cell lines. Anticancer Res. 2007;27(6B):4101–4106.
   PubMed Web of Science ®Google Scholar
• Bhattacharya B, Mukherjee S. Cancer therapy using antibiotics. J Cancer Ther. 2015;6(10):849. doi:10.4236/jct.2015.610093.
   Google Scholar
• Li J-M, Yang Y, Zhu P, Zheng F, Gong F-L, Mei Y-W. Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells. Immunopharmacol Immunotoxicol. 2012;34(1):36–41. doi:10.3109/08923973.2011.572890.
   PubMed Web of Science ®Google Scholar
• Enache M, Toader A, Enache M. Mitoxantrone-surfactant interactions: a physicochemical overview. Molecules. 2016;21(10):1356. doi:10.3390/molecules21101356.
   Web of Science ®Google Scholar
• Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63(12 suppl 6):S15–S18. doi:10.1212/WNL.63.12_suppl_6.S15.
   PubMed Web of Science ®Google Scholar
• Wichert A, Stege A, Midorikawa Y, Holm PS, Lage H. Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene. 2004;23(4):945. doi:10.1038/sj.onc.1207237.
   PubMed Web of Science ®Google Scholar
• Rahaman ST. Bleomycin: an overview on anti cancer drug. Int J Recent Advances in Multi Res. 2018;5(2):3618–3622.
   Google Scholar
• Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev. 2003;29(5):371–387. doi:10.1016/S0305-7372(03)00073-2.
   PubMed Web of Science ®Google Scholar
• Li X, Lan Y, He Y, Liu Y, Luo H, Yu H, Song N, Ren S, Liu T, Hao C. Heparan Sulfate and Chondroitin Sulfate Glycosaminoglycans Are Targeted by Bleomycin in Cancer Cells. Cellular physiology and biochemistry 2017; 43:1220–34
   PubMedGoogle Scholar
• Gazitaeva ZI, Drobintseva AO, Chung Y, Polyakova VO, Kvetnoy IM. Cosmeceutical product consisting of biomimetic peptides: antiaging effects in vivo and in vitro. Clin Cosmet Investig Dermatol. 2017;10(11).
   PubMedGoogle Scholar
• Tanaka Y, Tateishi R, Koike K. Proteoglycans are attractive biomarkers and therapeutic targets in hepatocellular carcinoma. Int J Mol Sci. 2018;19(10):3070. doi:10.3390/ijms19103070.
   PubMed Web of Science ®Google Scholar
• Rapraeger AC. Synstatin: a selective inhibitor of the syndecan‐1‐coupled IGF1R–αvβ3 integrin complex in tumorigenesis and angiogenesis. Febs J. 2013;280(10):2207–2215.
   PubMed Web of Science ®Google Scholar
• Metwaly HA, El-Gayar AM, El-Shishtawy MM. Inhibition of the signaling pathway of syndecan-1 by synstatin: A promising anti-integrin inhibitor of angiogenesis and proliferation in HCC in rats. Archives of biochemistry and biophysics; 2018.
   Google Scholar
• Bracci L, Mandarini E, Brunetti J, Depau L, Pini A, Terzuoli L, Scali S, Falciani C. The GAG-specific branched peptide NT4 reduces angiogenesis and invasiveness of tumor cells. PloS one 2018; 13:e0194744
   PubMed Web of Science ®Google Scholar
• Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PloS one 2011; 6:e21106
   Google Scholar
• Galcheva-Gargova Z, Chu CL, Long A, Duffner J, Holte K, Schultes BC. Role of M402, a novel heparan sulfate mimetic, in pancreatic cancer cell invasion and metastasis: Inhibition of the Sonic Hedgehog pathway and heparanase activity. Journal of Clinical Oncology 2012; 30: 25–
   Google Scholar
• Dredge K, Hammond E, Handley P, Gonda T, Smith M, Vincent C, Brandt R, Ferro V, Bytheway I. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. British journal of cancer 2011; 104: 635
   Google Scholar
• Hammond E, Brandt R, Dredge K. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PloS One. 2012;7(12):e52175. doi:10.1371/journal.pone.0052175.
   PubMed Web of Science ®Google Scholar
• Liao B-Y, Wang Z, Hu J, Liu W-F, Shen Z-Z, Zhang X, Yu L, Fan J, Zhou J. PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection. Tumor Biology 2016; 37:2987–98
   Google Scholar
• Coleman R. Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer. 2007;7:S29–S35.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA oncology 2017; 3:906–12
   PubMed Web of Science ®Google Scholar
• Coleman R, Body -J-J, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014;25(suppl_3):iii124–iii137. doi:10.1093/annonc/mdu103.
   PubMedGoogle Scholar
• Hadji P, Coleman RE, Wilson C, Powles T, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology 2015; 27:379–90
   Google Scholar
• Dedes P, Gialeli C, Tsonis A, Kanakis I, Theocharis A, Kletsas D, Tzanakakis G, Karamanos N. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochimica et Biophysica Acta (BBA)-General Subjects
   Google Scholar
• Siddikuzzaman GC, Berlin Grace V. All trans retinoic acid and cancer. Immunopharmacol Immunotoxicol. 2011;33(2):241–249. doi:10.3109/08923973.2010.521507.
   PubMed Web of Science ®Google Scholar
• Lokman NA, Ho R, Gunasegaran K, Bonner WM, Oehler MK, Ricciardelli C. Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer. J Exp & Clin Cancer Res. 2019;38(1):10. doi:10.1186/s13046-018-1017-7.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao J, Sun J, Huang L, Li Q. Targeting lung cancer initiating cells by all‑trans retinoic acid‑loaded lipid‑PLGA nanoparticles with CD133 aptamers. Exp Ther Med. 2018;16(6):4639–4649.
   PubMed Web of Science ®Google Scholar
• Connolly RM, Nguyen NK, Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res. 2013;19(7):1651–1659. doi:10.1158/1078-0432.CCR-12-3175.
   PubMed Web of Science ®Google Scholar
• Tran-Lundmark K, Tannenberg P, Rauch BH, Ekstrand J, Tran PK, Hedin U, Kinsella MG. Perlecan Heparan Sulfate Is Required for the Inhibition of Smooth Muscle Cell Proliferation by All-trans-Retinoic Acid. J Cell Physiol. 2015 Feb;230(2):482–7. doi:10.1002/jcp.24731. PMID: 25078760
   Google Scholar
• Ramya D, Siddikuzzaman, Grace VB. Effect of all-trans retinoic acid (ATRA) on syndecan-1 expression and its chemoprotective effect in benzo (α) pyrene-induced lung cancer mice model. Immunopharmacol Immunotoxicol. 2012;34(6):1020–1027. doi:10.3109/08923973.2012.693086.
   PubMed Web of Science ®Google Scholar
• Kumar B, Singh S, Skvortsova I, Kumar V. Promising targets in anti-cancer drug development: recent updates. Curr Med Chem. 2017;24(42):4729–4752.
   PubMed Web of Science ®Google Scholar